|
Repeated centralized MDT resectability assessment during first-line treatment in 1086 Finnish metastatic colorectal cancer (mCRC) patients nationwide (prospective RAXO study). |
|
|
Consulting or Advisory Role - Amgen; Bayer; Celgene; Eisai; Lilly; Merck Serono; Roche; Sanofi; Servier/Shire |
Speakers' Bureau - Prime Oncology |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Nordic Drugs (Inst); Roche (Inst); Sanofi (Inst); Servier (Inst) |
Travel, Accommodations, Expenses - Abbvie; Pierre Fabre |
|
|
Consulting or Advisory Role - Amgen; Bayer; Celgene; Lilly; Merck Serono; Roche; Sanofi; SERVIER |
Research Funding - Amgen (Inst); Lilly (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst) |
Travel, Accommodations, Expenses - Amgen; Merck; MSD; Roche |
|
|
Research Funding - Amgen (Inst); Lilly (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst) |
|
|
Consulting or Advisory Role - Amgen; Bayer; Celgene; Lilly; Merck; Roche; Sanofi; SERVIER |
Research Funding - Amgen (Inst); Celgene (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst) |
Travel, Accommodations, Expenses - Roche |
|
|
Consulting or Advisory Role - Amgen; Bayer; Celgene; Lilly; Merck; Roche; Sanofi; SERVIER |
Research Funding - Amgen (Inst); Lilly (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst) |
Patents, Royalties, Other Intellectual Property - One of the inventors in a patent: Method for selecting patients for treatment with an egfr inhibitor US 20110217296 A1 (Inst) |
Travel, Accommodations, Expenses - Amgen; Merck; MSD; Roche; Varian Medical Systems |
|
|
Consulting or Advisory Role - Amgen; Amgen (I); Bayer; Celgene; Grex Medical; Grex Medical (I); Lilly; Merck; Merck (I); Novartis (I); Roche; Sanofi; SERVIER |
Research Funding - Amgen; Lilly; Merck; Roche; Sanofi; SERVIER |
Travel, Accommodations, Expenses - Astellas Pharma (I); Celgene; Grex Medical (I); MSD; Teva (I) |
|
|
Consulting or Advisory Role - Amgen; Bayer; Celgene; Lilly; Merck; Roche; Sanofi; SERVIER |
Research Funding - Amgen (Inst); Lilly (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst) |
Travel, Accommodations, Expenses - Kyowa Hakko Kirin |
|
|
Consulting or Advisory Role - Amgen; Bayer; Celgene; Lilly; Merck; Roche; Sanofi; SERVIER |
Research Funding - Amgen (Inst); Lilly (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst) |
Travel, Accommodations, Expenses - Amgen; Ipsen; Kyowa Hakko Kirin; Roche |
|
|
Consulting or Advisory Role - Amgen; Bayer; Celgene; Lilly; Merck; Roche; Sanofi; SERVIER |
Research Funding - Amgen (Inst); Lilly (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst) |
Travel, Accommodations, Expenses - Merck; Pierre Fabre; Roche |
|
|
Consulting or Advisory Role - Amgen; Bayer; Celgene; Lilly; Merck; Roche; Sanofi; SERVIER |
Research Funding - Amgen (Inst); Lilly (Inst); Merck (Inst); MSD Oncology (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst) |
Patents, Royalties, Other Intellectual Property - Method for selecting patients for treatment with an egfr inhibitor US 20110217296 A1 (Inst) |
Travel, Accommodations, Expenses - Amgen; Ipsen; Roche; Sanofi |
|
|
Consulting or Advisory Role - Amgen; Ipsen; Lilly; Merck; Roche; Sanofi; SERVIER |
Research Funding - Amgen (Inst); Lilly (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst) |
Travel, Accommodations, Expenses - Helsinki University Hospital; Radiological Society of Finland |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Lilly; Merck; Roche (I); Sanofi; SERVIER |
Research Funding - Amgen (Inst); Lilly (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst) |
|
|
Consulting or Advisory Role - Amgen; Bayer; Celgene; Lilly; Merck; Roche; Sanofi; SERVIER |
Research Funding - Amgen (Inst); Lilly (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst) |
Travel, Accommodations, Expenses - GlaxoSmithKline; Kyowa Hakko Kirin |
|
|
Consulting or Advisory Role - Amgen; Bayer; Celgene; Lilly; Merck; Pfizer; Roche; Sanofi; SERVIER |
Research Funding - Abbvie (Inst); Amgen (Inst); Lilly (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst) |
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; MSD; Pfizer; Sanofi |
|
|
Consulting or Advisory Role - Amgen; Bayer; Celgene; Lilly; Merck; Roche; Sanofi; SERVIER |
Research Funding - Amgen (Inst); Lilly (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Docrates Cancer Center |
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Ipsen; Merck Serono; Roche |
Consulting or Advisory Role - AstraZeneca; Pierre Fabre; Takeda |
Research Funding - Amgen; Roche |
Travel, Accommodations, Expenses - Merck; Novartis; Teva |
Other Relationship - BiopSense |
|
|
Other Relationship - Boehringer Ingelheim |
|
|
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Celgene; Lilly; Merck; Roche; Sandoz; Sanofi; SERVIER |
Research Funding - Amgen (Inst); Lilly (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma |